"Ente strumentale attraverso il quale la Regione assicura i livelli essenziali ed uniformi di assistenza dell’ambito territoriale della Romagna"

During the past decade, Azienda Unita Sanitaria Locale di Ravenna conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 6 clinical trials were completed, i.e. on average, 28.6% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 6 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Azienda Unita Sanitaria Locale di Ravenna" #1 sponsor was "Fondazione Italiana Linfomi ONLUS" with 8 trials, followed by "AGC Biologics S.p.A." with 2 trials sponsored, "Ariad Pharmaceuticals" with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored and "Amgen" with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Unita Sanitaria Locale di Ravenna" #1 collaborator was "Chugai Pharmaceutical" with 2 trials as a collaborator, "ASST Cremona" with 1 trials as a collaborator, "AUSL Romagna Rimini" with 1 trials as a collaborator, "Arcispedale Santa Maria Nuova-IRCCS" with 1 trials as a collaborator and "Azienda Usl di Bologna" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Azienda Unita Sanitaria Locale di Ravenna" are "Paroxysmal Nocturnal Hemoglobinuria" (3 trials), "Non-Small Cell Lung Cancer" (2 trials), "ALK-positive Advanced NSCLC" (1 trials), "Acute Coronary Syndrome" (1 trials) and "Advanced Malignancies" (1 trials). Many other conditions were trialed in "Azienda Unita Sanitaria Locale di Ravenna" in a lesser frequency.

Most popular intervention types in "Azienda Unita Sanitaria Locale di Ravenna" are "Drug" (25 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Eculizumab" (3 trials), "Brigatinib" (2 trials), "Crovalimab" (2 trials), "Paclitaxel" (2 trials) and "Placebo" (2 trials). Other intervention names were less common.

The vast majority of trials in "Azienda Unita Sanitaria Locale di Ravenna" are 23 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Azienda Unita Sanitaria Locale di Ravenna". undefined are not yet recruiting, 4 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Azienda Unita Sanitaria Locale di Ravenna, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Azienda Unita Sanitaria Locale di Ravenna, 2 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Azienda Unita Sanitaria Locale di Ravenna has several departments that took part in Clinical trials: "Ausl Della Romagna, Ospedale "Infermi" - Rimini - Uo Ematologia" - 18 trials, "Ospedale Infermi Di Rimini; Unità Operativa di Oncologia e Oncoematologia" - 14 trials, "Dipartimento Oncologico - Ospedale S.Maria delle Croci" - 34 trials, "Ospedale Morgagni-Pierantoni; U.O. Pneumologia" - 4 trials, "Ospedale Infermi - UO Cardiologia" - 4 trials, "Ospedale M.Bufalini, U.O. Di Cardiologia-Utic" - 3 trials, "Ospedale Pierantoni, Divisione di Oncologia Medica" - 2 trials, "Ospedale delle Croci - Ematologia" - 29 trials, "U.O Pediatria Ospedale Infermi Azienda USL Rimini" - 2 trials, "Ospedale G. Ceccarini - Cardiologia-Utic" - 2 trials, "Ospedale Civile, U.O. Di Cardiologia" - 2 trials